Physician profile
Helen E Heiskell
NPI 1649805615
$5,397.20
in general payments reported to CMS, 2019-2025
37 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $703 · 2022: $1,488 · 2023: $1,382 · 2024: $900 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $593.87 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $508.68 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $443.33 | 2021-2024 | Jardiance, Trulicity, Mounjaro |
| Abbvie INC. | $402.39 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $398.09 | 2022-2024 | |
| Novo Nordisk INC | $293.05 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $269.42 | 2023-2025 | Gemtesa |
| Organogenesis INC. | $243.20 | 2022 | |
| Merck Sharp & Dohme LLC | $214.15 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $203.71 | 2022-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.99 | 2021-2023 | Ofev, Jardiance |
| Gilead Sciences, INC. | $186.69 | 2024-2025 | Epclusa |
| Exact Sciences Corporation | $166.06 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $139.52 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $138.36 | 2024-2025 | Otezla, Repatha, Otezla |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Heiskell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.